Prognostic relevance of insulin resistance on disease-free survival in head and neck squamous cell carcinomas: Preliminary results
Por:
Aviles-Jurado, FX, Flores, JC, Guma, J, Ceperuelo-Mallafre, V, Casanova-Marques, R, Gomez, D, Vendrell, JJ, Leon, X, Vilaseca, I, Terra, X
Publicada:
1 dic 2017
Resumen:
Background: The primary purpose of this study was to investigate the significance of pretreatment glycemic parameters in the prognosis of head and neck squamous cell carcinoma (HNSCC).
Methods: Plasma samples of 71 patients with untreated HNSCC were obtained at the time of diagnosis. The prognostic value of fasting insulin, glucose, glycosylated hemoglobin levels, and the homeostatic model of risk assessment-insulin resistance (HOMA-IR) was evaluated toward disease-free survival.
Results: High HOMA-IR levels were associated with poor disease-free survival in intermediate-advanced stage tumors. Kaplan-Meier curves showed lower disease-free survival rates in patients with high HOMA-IR than in patients with low levels. In patients with intermediate-advanced stage tumors, multivariate analysis revealed that those with an HOMA-IR > 2.974 presented a 2.7 times higher risk of poor outcome (95% confidence interval [CI] 1.023-7.341; P = .045).
Conclusion: The HOMA-IR is independently associated with disease-free survival in patients with HNSCC. We found an optimal HOMA-IR cutoff value for disease-free survival in patients with intermediate- advanced HNSCC.
Filiaciones:
Aviles-Jurado, FX:
Hosp Clin Barcelona, Otorhinolaryngol Head & Neck Surg Dept, Villarroel 170, Barcelona 08036, Catalonia, Spain
Univ Rovira & Virgili, Inst Invest Sanitaria Pere Virgili, Otolaryngol Dis Res Grp HJ23, Tarragona, Catalonia, Spain
Flores, JC:
Univ Rovira & Virgili, Inst Invest Sanitaria Pere Virgili, Otolaryngol Dis Res Grp HJ23, Tarragona, Catalonia, Spain
Univ Rovira & Virgili, Hosp Univ Tarragona Joan 23, Inst Invest Sanitaria Pere Virgili, Otorhinolaryngol Head & Neck Surg Dept, Tarragona, Catalonia, Spain
Guma, J:
Univ Rovira & Virgili, Hosp Univ Sant Joan Reus, IISPV, Oncol Dept, Catalonia, Spain
Ceperuelo-Mallafre, V:
Ctr Invest Biomed Red Diabet & Enfermedades Metab, Madrid, Spain
Casanova-Marques, R:
Univ Rovira Virgili, Sch Med, Tarragona, Catalonia, Spain
Gomez, D:
Hosp Univ Sant Joan Reus, Radiat Oncol Dept, Catalonia, Spain
Vendrell, JJ:
Ctr Invest Biomed Red Diabet & Enfermedades Metab, Madrid, Spain
Univ Rovira & Virgili, Inst Invest Sanitaria Pere Virgili, Hosp Univ Tarragona Joan 23, Endocrinol Dept, Tarragona, Catalonia, Spain
Leon, X:
Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Otorhinolaryngol Head & Neck Surg Dept, Barcelona, Spain
Univ Autonoma Barcelona, Networking Res Ctr Bioengn Biomat & Nanomed, CIBER BBN, MICINN,ISCIII, Barcelona, Spain
Vilaseca, I:
Hosp Clin Barcelona, Otorhinolaryngol Head & Neck Surg Dept, Villarroel 170, Barcelona 08036, Catalonia, Spain
Univ Barcelona, Ctr Invest Biomed Red Enfermedades Resp CIBER Res, Barcelona, Spain
Terra, X:
Univ Rovira & Virgili, Biochem & Biotechnol Dept, MoBioFood Res Grp, Campus Sescel Lades, Tarragona, Spain
|